FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197741978> ?p ?o ?g. }

• W3197741978 endingPage "S357" @default.
• W3197741978 startingPage "S357" @default.
• W3197741978 abstract "Thromboembolic events and bleeding episodes are the main complications of myeloproliferative neoplasms (MPNs). JAK2V617Fmutation is a known thrombotic risk factor in MPNs, while few data correlate JAK2V617F with bleeding risk. Therefore, the thrombosis/hemorrhage risk reassessment in MPN patients should be reappraised. The aim of our study is to evaluate the impact of JAK2V617V mutation positivity on bleeding complications in MPNs. A cross-sectional study was performed at two tertiary centers in upper Egypt, Assiut and Qena University Hospitals, from January 2019 to December 2020. Newly diagnosed MPN patients underwent history taking, physical examination, basic laboratory work, and molecular assessment of both the JAK2V617Vmutation and Philadelphia chromosome. The cohort included 78 Philadelphia-negative MPN patients, 55% of whom were female, and the median age was 57 (range 40–85). Half of the patients were polycythemia rubra vera (PRV; n=40, 51%), while one-third were primary myelofibrosis (PMF; n=28, 36%), and only 13% were essential thrombocytosis (ET; n=10). The median total leukocytic count (TLC) was 9.6 (range: 0.3–190) × 109/L, median hemoglobin level (HB) was 15 (range: 4–21) g/dl, and median platelet count was 359 (range: 3–2960) × 109/L. Almost half of the patients (n=35; 45%) harbor JAK2V617F. Regarding patients’ clinical criteria based on JAK2V617V mutation, there was no significant difference in itching (6% for JAK2V617F-positive group vs 9% JAK2V617F-negative group, P=0.6) and splenomegaly (71% vs 67%, P=0.8). Erythema was significantly higher in the JAK2V617F-positive group (34% vs 14%; P=0.0008). The main observation was that thrombosis occurred significantly more often in the JAK2V617V-positive group (49% vs 16%; P=0.0003). On the contrary, there was no significant difference in bleeding between the JAK2V617F-positive (23%) and JAK2V617F-negative groups (28%; P=0.6). A multivariate model was performed to identify the significant independent variables that lead to bleeding, which showed that only platelets (odds ratio=1) and splenomegaly (odds ratio=8.5) had significant effects. In conclusion, the data confirmed that JAK2V617V mutation is associated with an increased risk of thrombosis in MPNs, but it does not have a role in increased bleeding risk in MPNs. Large prospective studies are needed to confirm the role of JAK2V617V in bleeding during the course of MPNs and its relation to different lines of treatment." @default.
• W3197741978 created "2021-09-13" @default.
• W3197741978 creator A5001507418 @default.
• W3197741978 creator A5012903133 @default.
• W3197741978 creator A5020361326 @default.
• W3197741978 date "2021-09-01" @default.
• W3197741978 modified "2023-09-27" @default.
• W3197741978 title "MPN-207: Is the Absence of JAK2V617F Mutation a Risk Factor for Bleeding in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms?" @default.
• W3197741978 doi "https://doi.org/10.1016/s2152-2650(21)01824-3" @default.
• W3197741978 hasPublicationYear "2021" @default.
• W3197741978 type Work @default.
• W3197741978 sameAs 3197741978 @default.
• W3197741978 citedByCount "0" @default.
• W3197741978 crossrefType "journal-article" @default.
• W3197741978 hasAuthorship W3197741978A5001507418 @default.
• W3197741978 hasAuthorship W3197741978A5012903133 @default.
• W3197741978 hasAuthorship W3197741978A5020361326 @default.
• W3197741978 hasConcept C126322002 @default.
• W3197741978 hasConcept C141071460 @default.
• W3197741978 hasConcept C2778837598 @default.
• W3197741978 hasConcept C2779121184 @default.
• W3197741978 hasConcept C2779788118 @default.
• W3197741978 hasConcept C2780007613 @default.
• W3197741978 hasConcept C2780076729 @default.
• W3197741978 hasConcept C2780868729 @default.
• W3197741978 hasConcept C2781057849 @default.
• W3197741978 hasConcept C50440223 @default.
• W3197741978 hasConcept C71924100 @default.
• W3197741978 hasConcept C72563966 @default.
• W3197741978 hasConcept C89560881 @default.
• W3197741978 hasConcept C90924648 @default.
• W3197741978 hasConceptScore W3197741978C126322002 @default.
• W3197741978 hasConceptScore W3197741978C141071460 @default.
• W3197741978 hasConceptScore W3197741978C2778837598 @default.
• W3197741978 hasConceptScore W3197741978C2779121184 @default.
• W3197741978 hasConceptScore W3197741978C2779788118 @default.
• W3197741978 hasConceptScore W3197741978C2780007613 @default.
• W3197741978 hasConceptScore W3197741978C2780076729 @default.
• W3197741978 hasConceptScore W3197741978C2780868729 @default.
• W3197741978 hasConceptScore W3197741978C2781057849 @default.
• W3197741978 hasConceptScore W3197741978C50440223 @default.
• W3197741978 hasConceptScore W3197741978C71924100 @default.
• W3197741978 hasConceptScore W3197741978C72563966 @default.
• W3197741978 hasConceptScore W3197741978C89560881 @default.
• W3197741978 hasConceptScore W3197741978C90924648 @default.
• W3197741978 hasLocation W31977419781 @default.
• W3197741978 hasOpenAccess W3197741978 @default.
• W3197741978 hasPrimaryLocation W31977419781 @default.
• W3197741978 hasRelatedWork W10206933 @default.
• W3197741978 hasRelatedWork W10405791 @default.
• W3197741978 hasRelatedWork W11910675 @default.
• W3197741978 hasRelatedWork W12857734 @default.
• W3197741978 hasRelatedWork W13500216 @default.
• W3197741978 hasRelatedWork W19344179 @default.
• W3197741978 hasRelatedWork W19426974 @default.
• W3197741978 hasRelatedWork W19641110 @default.
• W3197741978 hasRelatedWork W20724425 @default.
• W3197741978 hasRelatedWork W2933528 @default.
• W3197741978 hasVolume "21" @default.
• W3197741978 isParatext "false" @default.
• W3197741978 isRetracted "false" @default.
• W3197741978 magId "3197741978" @default.
• W3197741978 workType "article" @default.